GlassScriptPhysician profile
Hung D Nguyen
NPI 1740395607
$2,180.67
in general payments reported to CMS, 2019-2025
22 companies · $748 in 2025
The $748 reported for 2025 was more than what 80% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $180 · 2020: $15.25 · 2021: $160 · 2022: $224 · 2023: $398 · 2024: $455 · 2025: $748.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,358 · Education: $244.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,357.50 |
| Education | $243.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $325.48 | 2019-2025 | Airsupra, Breztri |
| Glaxosmithkline, LLC. | $306.73 | 2019-2025 | Trelegy Ellipta, Nucala |
| Actelion Pharmaceuticals US, INC. | $225.13 | 2023-2024 | Uptravi, Opsumit |
| Harmony Biosciences LLC | $212.31 | 2022-2025 | Wakix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $179.99 | 2022-2025 | Jascayd |
| Ethicon INC. | $130.83 | 2021 | |
| Shionogi INC | $124.92 | 2024 | Fetroja |
| Genzyme Corporation | $95.55 | 2024-2025 | |
| Amgen INC. | $95.28 | 2024-2025 | Tezspire |
| Nestle Healthcare Nutrition INC. | $89.02 | 2021-2022 | |
| Insmed, INC. | $81.11 | 2023-2025 | Arikayce |
| Grifols USA, LLC | $50.96 | 2025 | Prolastin-C Liquid |
| Takeda Pharmaceuticals U.S.A., INC. | $49.49 | 2023 | Glassia |
| Abiomed | $37.95 | 2024 | Impella |
| Viatris Specialty LLC | $34.38 | 2025 | Yupelri |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Verona Pharma, INC. | $29.08 | 2025 | Ohtuvayre |
| Sumitomo Pharma America, INC. | $23.66 | 2024 | Gemtesa |
| Merck Sharp & Dohme LLC | $23.54 | 2023 | Belsomra |
| Jazz Pharmaceuticals INC. | $22.73 | 2019 | |
| Zyla Life Sciences, INC. | $15.25 | 2020 | |
| Axsome Therapeutics, INC. | $14.30 | 2025 | Sunosi |
| Arbor Pharmaceuticals, INC. | $12.98 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hung Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.